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Introduction
Patients with severe asthma generally benefit from consultations with an asthma specialist to optimise
their management, which may include the potential initiation of biologic agents that have made a
breakthrough in the treatment of severe disease.
Omalizumab, a monoclonal antibody (mAb) against immunoglobulin E (anti-IgE), was the first biologic
developed for the treatment of severe allergic asthma and consistent results of randomised controlled trials
(RCTs) [1] or real life trials [2] demonstrated a reduction of severe exacerbations in adults and children [3].
Some nonatopic asthma patients may also benefit from omalizumab [4]. Further investigation is needed to
better assess its clinical efficacy in this setting, and to identify predictors of the treatment response.
Eosinophils are important cells in asthma. Mepolizumab or reslizumab, anti-interleukin-5 (anti-IL-5)
mAbs or benralizumab, an anti-IL-5 receptor mAb, are effective in reducing exacerbations in patients with
severe eosinophilic asthma [5].
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Other biologics targeting different pathways of asthma are in development. Dupilumab, an mAb against
IL-4-receptor-α blocking IL-4/IL-13, has promising results [6].
Different biologics targeting IgE and IL-5 are currently available, but physicians have difficulty in
prioritising the optimal one for a given patient. This is due to overlaps in patient populations who could
qualify for different biologics, since direct comparisons do not exist and meta-analyses of these treatments
cannot be conclusive [7, 8]. Care pathways are needed to help physicians stratify their patients with severe
asthma [9] to select an appropriate biologic.
From guidelines to care pathways
Integrated care pathways (ICPs) are structured multidisciplinary care plans detailing essential patient
management steps. They promote the translation of guidelines into protocols and their subsequent
application to clinical practice. They also empower patients and health and social care professionals. ICPs
differ from practice guidelines as they are utilised by a multidisciplinary team and focus on the quality and
co-ordination of care. ICPs, the standard of care in oncology or palliative care, have already been proposed
for asthma, chronic obstructive pulmonary disease and allergic rhinitis [10] and have been digitalised [11, 12].
TABLE 1 National Institute for Health and Care Excellence, UK (NICE) guidance for omalizumab, mepolizumab and reslizumab
Omalizumab for treating severe persistent allergic asthma
Omalizumab (Xolair, Novartis) is a monoclonal antibody that binds to IgE. It has a UK marketing authorisation as add-on therapy to improve
control of asthma in adults and adolescents (those aged 12 years and over) and children (those aged 6–11 years) with severe persistent
allergic asthma who have:
A positive skin test or in vitro reactivity to a perennial aeroallergen
Reduced lung function (FEV1 <80% in adults and adolescents)
Frequent daytime symptoms or night-time awakenings
Multiple documented severe exacerbations despite daily high-dose plus LABA
The marketing authorisation states that omalizumab treatment “should only be considered for patients with convincing IgE mediated asthma”.
It also specifies that, 16 weeks after the start of omalizumab, physicians should assess how effective the treatment is, and should continue
omalizumab only in patients whose asthma has markedly improved. It also specifies that omalizumab should be initiated and monitored in a
specialist centre by a physician experienced in the diagnosis and treatment of severe persistent asthma.
Mepolizumab for treating severe refractory eosinophilic asthma
Mepolizumab, as an add-on to optimised standard therapy, is recommended as an option for treating severe refractory eosinophilic asthma in
adults, only if:
The blood eosinophil count is ⩾300 cells per μL or more in the previous 12 months, and
The person has agreed to and followed the optimised standard treatment plan, and
Has had four or more asthma exacerbations needing systemic corticosteroids in the previous 12 months, or
Has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months, and
The company provides the drug with the discount agreed in the patient access scheme
At 12 months of treatment:
Stop mepolizumab if the asthma has not responded adequately, or
Continue treatment if the asthma has responded adequately and assess response each year
An adequate response is defined as:
At least 50% fewer asthma exacerbations needing systemic corticosteroids in those people with four or more exacerbations in the previous
12 months, or
A clinically significant reduction in continuous oral corticosteroid use while maintaining or improving asthma control
Reslizumab for treating eosinophilic asthma
Reslizumab, as an add-on therapy, is recommended as an option for the treatment of severe eosinophilic asthma that is inadequately
controlled in adults despite maintenance therapy with high-dose ICS plus another drug, only if:
The blood eosinophil count has been recorded as ⩾400 cells per μL
The person has had three or more asthma exacerbations in the past 12 months, and
The company provides reslizumab with the discount agreed in the patient access scheme
At 12 months:
Stop reslizumab if the asthma has not responded adequately, or
Continue reslizumab if the asthma has responded adequately and assess response each year
An adequate response is defined as:
A clinically meaningful reduction in the number of severe exacerbations needing systemic corticosteroids, or
A clinically significant reduction in continuous oral corticosteroid use while maintaining or improving asthma control
For omalizumab, data from [17] (published in April 2013 and evidence reviewed again in March 2016 with no changes to the recommendations);
for mepolizumab, data sourced from NICE (www.nice.org.uk/guidance/ta431; published January 2017) and for reslizumab, data sourced from
NICE (www.nice.org.uk/guidance/gid-ta10036/documents/final-appraisal-determination-document). Ig: immunoglobulin; FEV1: forced
expiratory volume in 1 s; LABA: long-acting inhaled beta-2 agonist; ICS: inhaled corticosteroid.
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Care pathways in severe asthma
The definition of asthma severity, control and exacerbations was proposed to the World Health
Organization (WHO) [13]. The consensus by U-BIOPRED (Unbiased Biomarkers for the Prediction of
respiratory disease outcomes) also provides an algorithm for severe asthma based on insufficient therapy,
poor treatment adherence and/or multimorbidity [14, 15]. More recently, the American Thoracic Society/
European Respiratory Society task force proposed recommendations for severe asthma in developed
countries [16].
In patients appropriately diagnosed, severe asthma is defined by the level of current clinical control and
risks as: “uncontrolled asthma which can result in the risk of frequent severe exacerbations (or death) and/
or adverse reactions to medications and/or chronic morbidity (including impaired lung function)” [13]. A
stepwise approach for ICPs in severe asthma was proposed to WHO in 2009 [13]. Patients requiring
biologics are those with uncontrolled asthma despite optimal pharmacological treatment.
All biologics approved for asthma by the European Medicines Agency (EMA) and the US Food and Drug
Administration (FDA) include stratified patients with severe asthma uncontrolled despite being on a high
dose controller therapy including at least inhaled corticosteroids (ICS) and severe exacerbations. In the
Global Initiative for Asthma (GINA) strategy, omalizumab, mepolizumab and reslizumab represent the
first (and, currently, only) therapies for severe asthma (step 5) (data sourced from GINA: ginasthma.org).
The National Institute for Health and Care Excellence, UK (NICE) proposed alternative guidance for
omalizumab in 2013 [17], reviewed in 2016, and for mepolizumab and reslizumab in 2017 (table 1).
Components of care pathways for biologics in asthma
Improvement of care pathways understanding the mechanisms
Mechanisms of action of biologics
Treatment options for severe asthma are mostly for the type 2 asthma phenotype characterised by a
prominent role of type 2 cytokines such as IL-4, IL-5 and IL-13, and IgE [18]. Mechanisms of action of
biologics need to be considered since omalizumab is indicated for moderate to severe allergic asthma
regardless of baseline eosinophil counts, whereas anti-IL-5 can be effective in both allergic and
non-allergic eosinophilic asthma.
Biomarkers are important to help guide individualised therapy in severe asthma, but available ones
represent imperfect discriminators for selecting the best option for individual patients [18]. The roles of
exhaled nitric oxide fraction (FeNO) and periostin are insufficiently understood while all available biologics
are effective in subjects with high eosinophil counts [19]. Furthermore, with current knowledge, the use of
existing biomarkers has not been helpful to assess efficacy in either the short or long term.
Anti-viral effects of omalizumab
Rhinoviruses represent the most common trigger of asthma exacerbations. Escalating ICS dose does not
reduce viral-induced wheeze whereas a study in inner city asthma children suggested that omalizumab
reduced viral exacerbations [20, 21]. In addition, omalizumab initiated 4–6 weeks before return to school
reduced exacerbations in the autumn. Moreover, omalizumab improved interferon-α responses to
rhinovirus and, within the omalizumab group, greater interferon-α increases were associated with fewer
exacerbations [22]. Finally, omalizumab shortens the frequency and duration of rhinovirus illnesses in
asthmatic children. These studies suggest that allergic inflammation is causing increased susceptibility to
viral illnesses [23].
Age
Omalizumab was approved in children above the age of 6 years by the EMA in 2009 and the FDA in 2016
[3]. The other existing biologics are not yet approved in children younger than 12 years.
Adjustment of dosage
Omalizumab is administered subcutaneously every 2–4 weeks based on baseline total IgE level and body
weight. Reslizumab is administered intravenously every 4 weeks based on body weight (3 mg·kg−1).
Mepolizumab is administered as a fixed dose subcutaneous injection every 4 weeks.
Stopping rules
Biologics are expensive treatments that should be continued for years when efficacious. It is therefore
important to assess whether they should be continued after a short course of treatment (e.g. less than
4 months: early stopping rule) and can be discontinued after a longer course of treatment (e.g. 3 years: late
stopping rule).
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Early stopping rule
The early stopping rule was investigated for omalizumab [24]. Baseline characteristics did not reliably
predict benefit with omalizumab. The global evaluation of treatment effectiveness by physicians after
16 weeks of treatment is the most meaningful measure of response to therapy. This was confirmed in all
RCTs or real life studies [25]. There are no data supporting a validated stopping rule for anti-IL-5 mAbs.
However, NICE has proposed guidance for a 12 month stopping rule for anti-IL-5 mAbs (table 1).
Late stopping rule
Few data are available to assist clinicians with decisions regarding long-term use of asthma biologics. A
prospective study evaluated the benefit and persistence of response in subjects continuing or withdrawing
from long-term omalizumab treatment [26]. More subjects in the omalizumab group (67%) had no
exacerbation compared to the placebo group (47.7%). Time to first exacerbation was also longer in the
omalizumab treated patients, and subjects continuing omalizumab had significantly better asthma control
than those who stopped. No late stopping rule study is available for anti-IL-5 mAbs.
Care pathways for a biologic in severe asthma
Patient stratification for biologics
Patient stratification for available biologic therapies is based mainly on clinical end points, allergy tests, IgE
levels and blood eosinophils (table 2). There are insufficient data for other biomarkers such as periostin or
FeNO. The optimal cut off level of eosinophils for initiation of anti-IL-5 is still subject to debate. A
minimal level of 150 per mm3 is often utilised for mepolizumab based on pivotal trials [27] but NICE has
proposed a higher level (table 1). A blood eosinophil count of 400 per mm3 is considered to be the
threshold for initiation of reslizumab [28].
Care pathway for biologics in severe asthma
Based on current knowledge, we propose an ICP for biologics in severe asthma to help physicians
distinguish patients eligible for omalizumab or anti-IL-5 mAbs using a simple stepwise approach (box 1).
This is based not only on efficacy and safety of the mAbs, but also on the availability of early stopping
rules and age (figure 1).
Conclusion
This manuscript deals with a rapidly changing field, and thus the proposals made should be regularly
updated [31]. A high level evidence for comparative efficacy and effectiveness of biologics in severe asthma
is lacking, since there are no head-to-head RCTs comparing anti-IgE and anti-IL5. There is a need for
platform trials in severe asthma comparing different biologics with each other, but also comparing other
pharmacological (e.g. long-acting muscarinic antagonists, azithromycin, oral prostaglandin D2 antagonists
(CRTH2 antagonists)) and non-pharmacological treatments (e.g. bronchial thermoplasty; pulmonary
rehabilitation; weight reduction) as an add-on or replacement of mAbs.
TABLE 2 Stratification of patients for biologics
Omalizumab Anti-IL-5 mAb
Primary mechanisms of action Anti-IgE Anti-IL-5
Other potential mechanisms of action Anti-rhinovirus
Biomarker for patient selection IgE to indoor aeroallergen Eosinophils
Stratification of the patient Severe asthma plus high dose controller (ICS) plus exacerbations
Efficacy RCTs and real life RCTs
Children ⩾6 years ⩾12 years
Patient selection Total IgE and BMI BMI for reslizumab
Administration Subcutaneous Mepolizumab: subcutaneous
Reslizumab: intravenous
Clinically relevant outcome Severe exacerbation
Safety 10 years of post-marketing surveillance; safe in phase III studies
Biomarker of efficacy Eosinophils
Demonstrated early stopping rule GETE (4 months) Unclear (12 months)
Late stopping rule Unclear
IL: interleukin; Ig: immunoglobulin; ICS: inhaled corticosteroid; RCT: randomised controlled trial; BMI: body mass index; GETE: global
evaluation of treatment effectiveness.
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Severe asthma uncontrolled despite optimal therapy according to guidelines
and severe exacerbation(s)
Yes No
Allergic asthma to perennial allergens
Total IgE within range omalizumab treatment
Omalizumab 16-week trial
High blood eosinophils
Anti-IL-5 mAb for 1 year
Non-effective (GETE)Effective (GETE)
Non-effectiveEffective
High blood eosinophils
Continue anti-IL-5 mAbContinue omalizumab
FIGURE 1 Care pathways for biologics in asthma. Ig: immunoglobulin; GETE: global evaluation of treatment
effectiveness; IL: interleukin; mAb: monoclonal antibody.
BOX 1 Integrated care pathway to help physicians distinguish which severe asthma patients are eligible for omalizumab or
anti-interleukin-5 monoclonal antibodies (anti-IL-5 mAbs)
Step 1
There are some simple situations:
For patients who are allergic but not eosinophilic (level <300 per mm3), omalizumab should be the first choice.
For patients who are not allergic and have a high blood eosinophil count (mepolizumab ⩾300 per mm3, reslizumab ⩾400 per mm3), anti-IL-5
mAbs should be considered first line [29].
For children aged 6 and <12 years of age that meet prescribing criteria, omalizumab is the only choice.
For patients who are both allergic and eosinophilic, and meet prescribing criteria for any of these agents, no direct comparative data
exist, meta-analyses are not informative and either of these classes of therapy may be considered as first line therapy. However, when
making the decision, clinicians should take into account the ability to stop omalizumab after 16 weeks, in combination with a large body of
real life data and over a decade of post marketing surveillance confirming its safety.
Step 2
For omalizumab-treated patients, after 16 weeks, global evaluation of treatment effectiveness should be assessed in omalizumab-treated
patients and a switch to anti-IL-5 mAb is proposed for those who did not respond and have a high blood eosinophil count. This is possible
since mepolizumab may be effective in patients previously treated by omalizumab [30].
For anti-IL-5 mAbs-treated patients, a relatively vague stopping rule is provided by NICE (table 1) at 12 months.
Importantly, there are no data examining combination therapy with different biologics for those who are partial responders.
There is a significant unmet need for therapies for individuals who have low eosinophil counts and who are not allergic. Bronchial thermoplasty
may be considered in this non-type 2 patient population and substantive workup should be undertaken to evaluate for compliance to
treatment, other asthma multimorbidities (e.g. acid reflux, rhinosinusitis), risk factors (e.g. smoking, allergen exposure) or differential
diagnosis (e.g. chronic obstructive pulmonary disease, aspiration, vocal cord dysfunction).
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